Precise clinical trials for severe asthma treatment are to come soon based on a study that identifies key inflammatory and immunological underpinnings of severe asthma.

TOP INSIGHT
A new study identifies key inflammatory and immunological underpinnings of severe asthma with implications for precise clinical trials and future treatment for severe asthma.
To model allergic lung inflammation in a dirty indoor environment, the team exposed a mouse model to a common environmental indoor allergen - house dust mite - as well as to endotoxin, a toxin released by bacterial cells. Exposure to both stimuli triggered complex lung inflammation, including a phenomenon known as lung NETosis.
In response to inflammatory triggers, white blood cells known as neutrophils form "neutrophil extracellular traps" (NETs). NETosis is the process by which NETs get activated and released. NETs can play a significant role in helping defend a host from invaders, but they can also cause organ injury and inflammation.
Vital NETosis is a process in which neutrophils extrude their nuclear material, including DNA, to form NETs and then reseal their membranes to create cytoplasts - cells that lack a nucleus. Levy and colleagues found that in their model, NETosis and cytoplasts appeared to play a key role in triggering and amplifying an allergen-initiated neutrophilic immune response in lung inflammation.
In addition to studying animals, the team also examined samples of fluid from the lungs of human severe asthma patients, finding that a subset of patients had high neutrophil counts and detectable NETs and cytoplasts - important implications for how to design more precise clinical trials for severe asthma treatment.
Source-Eurekalert
MEDINDIA



Email










